Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stake in Elevance Health, Inc. $ELV

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 53.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 106,042 shares of the company’s stock after purchasing an additional 37,090 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Elevance Health were worth $31,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Kemnay Advisory Services Inc. purchased a new position in Elevance Health in the 4th quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health during the 4th quarter valued at about $32,000. ORG Partners LLC boosted its holdings in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the last quarter. Dorato Capital Management bought a new stake in shares of Elevance Health in the fourth quarter worth approximately $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Elevance Health in the fourth quarter worth approximately $38,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Stock Performance

ELV opened at $416.97 on Friday. The company’s 50 day moving average is $389.48 and its 200 day moving average is $350.67. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a market cap of $90.55 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 2.36 and a beta of 0.67. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $427.19.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the prior year, the company earned $11.97 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 26.86 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date was Wednesday, June 10th. Elevance Health’s dividend payout ratio is 29.26%.

Insider Buying and Selling

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Truist Financial increased their price objective on shares of Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Evercore reiterated a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Morgan Stanley increased their price target on Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a report on Thursday, June 4th. JPMorgan Chase & Co. raised their price target on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Finally, Jefferies Financial Group cut their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $419.16.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.